Fujii, Takeo
Masuda, Hiroko
Cheng, Yee Chung
Yang, Fei
Sahin, Aysegul A.
Naoi, Yasuto
Matsunaga, Yuki
Raghavendra, Akshara
Sinha, Arup Kumar
Fernandez, Jose Rodrigo Espinosa
James, Anjali
Yamagishi, Keisuke
Matsushima, Tomoko
Schuetz, Robert
Tripathy, Debu
Tada, Sachiyo
Jackson, Rubie S.
Noguchi, Shinzaburo
Nakamura, Seigo
Acoba, Jared D.
Ueno, Naoto T. http://orcid.org/0000-0002-0166-7275
Funding for this research was provided by:
Morgan Welch Inflammatory Breast Cancer Research Program
State of Texas Rare and Aggresive Breast Cancer Research Program
National Cancer Institute (CA016672)
Article History
Received: 26 September 2020
Accepted: 28 May 2021
First Online: 15 June 2021
Declarations
:
: K.Y., T.M., and S.T. are employees of Sysmex Corporation (Curebest™ 95GC Breast service provider). Y.N. holds a joint patent on Curebest™ 95GC Breast with Sysmex Corporation, receive research funds from Sysmex and AstraZeneca, and received a lecture fee of 100,000 yen a year from Sysmex Corporation, AstraZeneca and Takeda. S.N. has received honoraria and research grants from Sysmex Corporation and has been an advisor for Sysmex Corporation and holds a joint patent on Curebest™ 95GC Breast with Sysmex. N.T.U. has research grants with Sysmex Corporation and with Genomic Health.
: This retrospective chart review with linked tissue analysis was approved by the central Institutional Review Boards at the five participating institutions in the USA and Japan: The University of Texas MD Anderson Cancer Center (protocol number: PA15-0905), University of Hawai’i Cancer Center (protocol number: RA-2017-021), Medical College of Wisconsin (protocol number: PRO00029366), Anne Arundel Medical Center (protocol number: 1056834), and Showa University (protocol number: 2383). A waiver of informed consent was granted based on the study’s retrospective nature.
: For this type of study, formal consent is not required.